Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

SELL
$0.28 - $1.16 $32,710 - $135,514
-116,823 Reduced 65.5%
61,535 $20,000
Q1 2024

Apr 22, 2024

SELL
$1.06 - $1.67 $1,390 - $2,191
-1,312 Reduced 0.73%
178,358 $206,000
Q4 2023

Jan 16, 2024

SELL
$1.26 - $1.79 $17,537 - $24,915
-13,919 Reduced 7.19%
179,670 $303,000
Q3 2023

Oct 24, 2023

BUY
$1.61 - $2.54 $13,612 - $21,475
8,455 Added 4.57%
193,589 $350,000
Q2 2023

Jul 25, 2023

BUY
$1.14 - $1.95 $11,869 - $20,303
10,412 Added 5.96%
185,134 $344,000
Q1 2023

Apr 14, 2023

BUY
$1.2 - $2.19 $9,652 - $17,616
8,044 Added 4.83%
174,722 $232,000
Q4 2022

Feb 08, 2023

SELL
$1.63 - $3.52 $20,314 - $43,869
-12,463 Reduced 6.96%
166,678 $281,000
Q3 2022

Oct 25, 2022

BUY
$0.73 - $3.74 $42,802 - $219,291
58,634 Added 48.66%
179,141 $559,000
Q2 2022

Aug 12, 2022

BUY
$2.2 - $4.2 $69,495 - $132,673
31,589 Added 35.53%
120,507 $287,000
Q1 2022

May 11, 2022

BUY
$2.83 - $8.69 $188,647 - $579,275
66,660 Added 299.49%
88,918 $358,000
Q4 2021

Feb 08, 2022

SELL
$8.31 - $14.92 $218,237 - $391,829
-26,262 Reduced 54.13%
22,258 $185,000
Q3 2021

Nov 02, 2021

BUY
$9.15 - $13.28 $443,958 - $644,345
48,520 New
48,520 $562,000

Others Institutions Holding DNA

About Ginkgo Bioworks Holdings, Inc.


  • Ticker DNA
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 1,287,779,968
  • Market Cap $13.2B
  • Description
  • Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agric...
More about DNA
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.